Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Review Article

COVID-19 Infection: A Review of Summarized Clinical Trials Study for the Treatment

Author(s): Afzal Hussain*, Ashfaq Hussain and Chandan Kumar Verma

Volume 2, Issue 4, 2021

Published on: 25 September, 2020

Page: [431 - 444] Pages: 14

DOI: 10.2174/2666796701999200925204309

Abstract

Background: Coronavirus Disease 2019 (COVID-19) is a widely infectious and pathogenic viral infection. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, and spread throughout the world. Coronavirus is indeed an enveloped RNA virus of the genus Betacoronavirus, which is transmitted to birds, humans as well as other mammals. The fastest human to human transition has been generally established. On July 19, 2020, the WHO has reported total confirmed cases: 1,40, 43,176, total confirmed new cases: 1,66,735, total deaths: 5,97,583, and total new deaths: 4,496 globally.

Material & Methods: In this review, the Clinical trial database is analyzed and systematically summarized drugs which are in the recruiting phase and the completion phase of the clinical trial.

Results: Total 383 clinical trials are listed, involving more than 350 medicines such as Deferoxamine, Favipiravir, DAS181, Tocilizumab Injection, Sarilumab, Placebo, Sildenafil citrate tablets, Sargramostim, Lopinavir/ritonavir, Remdesivir, Bevacizumab, Tetrandrine, Fingolimod, Methylprednisolone, Plaquenil, Tocilizumab, Hydroxychloroquine, Abidol hydrochloride, Bevacizumab Injection, Methylprednisolone, Amoxicillin-clavulanate, Moxifloxacin, Sarilumab, Darunavir, Cobicistat, etc.

Conclusion: There is no commercially authorized antiviral treatment or vaccine suitable for use against COVID-19. However, clinical trials represent an effective approach because they facilitate the development of new types of pharmaceutical drugs.

Keywords: COVID-19, pneumonia, WHO, drugs, infection, corona.

Graphical Abstract
[1]
Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003; 362(9393): 1353-8.
[http://dx.doi.org/10.1016/S0140-6736(03)14630-2] [PMID: 14585636]
[2]
Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23(8): 986-93.
[http://dx.doi.org/10.1038/cr.2013.92] [PMID: 23835475]
[3]
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[4]
Monchatre-Leroy E, Boué F, Boucher J-M, et al. Identification of alpha and beta coronavirus in wildlife species in France: bats, rodents, rabbits, and hedgehogs. Viruses 2017; 9(12): 364.
[http://dx.doi.org/10.3390/v9120364] [PMID: 29186061]
[5]
Sanjuán R, Domingo-Calap P. Mechanisms of viral mutation. Cell Mol Life Sci 2016; 73(23): 4433-48.
[http://dx.doi.org/10.1007/s00018-016-2299-6] [PMID: 27392606]
[6]
Chan JF-W, Kok K-H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9(1): 221-36.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]
[7]
Lai C-C, Shih T-P, Ko W-C, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3)105924
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[8]
Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization 2020.
[9]
Cohen J. Wuhan seafood market may not be source of novel virus spreading globallyScience 2020 Available from: https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally
[10]
Association CPM. Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association.An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19) Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41(2): 139-44.
[PMID: 32057211]
[11]
Bin SY, Heo JY, Song M-S, et al. Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea. Clin Infect Dis 2016; 62(6): 755-60.
[http://dx.doi.org/10.1093/cid/civ1020] [PMID: 26679623]
[12]
WHO Coronavirus disease (COVID-2019) situation reports 2020 Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
[13]
Administration USFD. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems 2020.Available from: . https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
[14]
Ng CS, Kasumba DM, Fujita T, Luo H. Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death. Cell Death Differ 2020; 27(8): 2363-82.
[http://dx.doi.org/10.1038/s41418-020-0509-0] [PMID: 32034313]
[15]
Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol 2019; 43101300
[16]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[17]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018; 9: e00221-18.
[18]
Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M, Eslami M. A global treatments for coronaviruses including COVID-19. J Cell Physiol 2020; 235: 9133-42.
[http://dx.doi.org/10.1002/jcp.29785] [PMID: 32394467]
[19]
Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: What’s next? Br J Pharmacol 2020; 177: 4813-24.
[http://dx.doi.org/10.1111/bph.15072] [PMID: 32329520]
[20]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[21]
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395(10223): e30-1.
[http://dx.doi.org/10.1016/S0140-6736(20)30304-4] [PMID: 32032529]
[22]
Holshue ML, DeBolt C, Lindquist S, et al. Washington state 2019-nCoV case investigation team. first case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[23]
Derebail VK, Falk RJ. ANCA-associated vasculitis—refining therapy with plasma exchange and glucocorticoids. N Engl J Med 2020; 382: 671-3.
[24]
Rashid M, Husain A, Shaharyar M, Mishra R, Hussain A, Afzal O. Design and synthesis of pyrimidine molecules endowed with thiazolidin-4-one as new anticancer agents. Eur J Med Chem 2014; 83: 630-45.
[http://dx.doi.org/10.1016/j.ejmech.2014.06.033] [PMID: 25010935]
[25]
Hussain A, Verma CK. A Combination of pharmacophore modeling, molecular docking and virtual screening study reveals 3, 5, 7-Trihydroxy-2-(3, 4, 5-trihydroxyphenyl)-4H- Chromen-4-One as a potential anti-cancer agent of COT kinase. Indian J Pharm Educ Res 2018; 52: 699-706.
[http://dx.doi.org/10.5530/ijper.52.4.81]
[26]
Hussain A. Molecular docking and in silico ADMET study reveals 3-(5-{[4- (aminomethyl) piperidin-1-yl] methyl}-1h-indol-2-yl)-1h-indazole-6-carbonitrile as a potential inhibitor of cancer Osaka thyroid kinase. Biomed Res 2017; 28: 5805-15.
[27]
Hussain A, Verma CK. Ligand- and structure-based pharmacophore modeling, docking study reveals 2-[[4-[6-(isopropylamino) pyrimidin-4-yl]-1H-pyrrolo[2,3-b] pyridin-6-yl] amino] ethanol as a potential anticancer agent of CDK9/cyclin T1 kinase. J Cancer Res Ther 2019; 15(5): 1131-40.
[http://dx.doi.org/10.4103/jcrt.JCRT_47_18] [PMID: 31603123]
[28]
Hussain A, Verma CK, Chouhan U. Identification of novel inhibitors against cyclin dependent kinase 9/Cyclin T1 complex as: Anti cancer agent. Saudi J Biol Sci 2017; 24(6): 1229-42.
[http://dx.doi.org/10.1016/j.sjbs.2015.10.003] [PMID: 28855816]
[29]
Hussain A, Verma CK. Recognition of new inhibitor of CDK9/Cyclin T1 complex as persuasive anticancer agent. Int J Adv Biotechnol Res 2016; 7: 654-68.
[30]
Hussain A, Verma CK. Next generation sequencing data analysis for unveiling critical genes in kidney tumor. Int J Adv Biotechnol Res 2016; 7: 2033-44.
[31]
Medicine USMLe Clinical studies related to the coronavirus disease (COVID-19) Available from: https://www.usmle.org/

© 2022 Bentham Science Publishers | Privacy Policy